Press release attachment.
Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
Earlier from Mesoblast
- Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
- Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
- Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
- Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
- Patient Recruitment Target Achieved in CLBP Pivotal Trial
Later from Mesoblast
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
- Major Milestone Treatment Completed in P3 Trial for CLBP
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast